Advanced Adjuvant Systems
SPI Pharma partners strategically to make affordable, stable vaccine adjuvants accessible worldwide. While past innovations were often costly, or unavailable for licensing, our mission is to deliver scalable, next-generation adjuvant systems that combine performance, stability, and commercial availability for global vaccine developers.
Powering the Next Generation of Vaccines
SPI Pharma, QVANT and Inimmune are redefining what’s possible in vaccine development with advanced adjuvant systems that spark stronger immune responses and speed innovation to market. Together, we’re uniting world-class science with global scale to bring breakthrough vaccine technologies to patients worldwide.
Our Portfolio of Adjuvants
Valens™ T4Q
Valens T4Q is a liposomal adjuvant system combining INI-2002, a fully synthetic TLR4 agonist, with QS-21. This formulation elicits robust Th1-biased immune responses, comparable to those achieved with approved adjuvant systems used in malaria and shingles vaccines that incorporate MPLA and QS-21. Valens T4Q is designed for applications requiring strong cellular immunity and enhanced immunogenicity. The adjuvant platform is protected by patents extending through 2039 and is available in two configurations: T4QGH, formulated with QS-21GH to enhance affordability, and T4QXP, formulated with high-grade QS-21XP (>95% purity).
Valens™ T4AH
ValensTM T4AH is an adjuvant system combining INI-2002, a fully synthetic TLR4 agonist, adsorbed onto aluminum hydroxide gel. By integrating aluminum hydroxide–mediated antigen presentation with targeted innate immune activation through TLR4 signaling, this combination enhances immune responses beyond those achieved with traditional aluminum-based adjuvants alone, resulting in higher and more durable antibody titers. Valens T4AH is particularly suitable for weakly immunogenic antigens and for vaccines where long-term protection is required. Its composition and mechanism of action are comparable to TLR4-based aluminum adjuvant systems approved for use in human vaccines, including those developed for HPV and hepatitis B.
T4SE (Pipeline Adjuvant)
T4SE is an oil-in-water squalene emulsion adjuvant system combined with INI-2002, a fully synthetic TLR4 agonist. The emulsion promotes efficient antigen delivery and immune cell recruitment at the injection site, while INI-2002 provides targeted innate immune activation through TLR4 signaling, resulting in enhanced and durable immune responses. T4SE supports potent antibody and adaptive immune responses, particularly in settings where dose sparing, rapid onset of immunity, or long-term protection are required. Its composition and functional profile are comparable to squalene-based oil-in-water adjuvant systems approved for use in human influenza vaccines, with the addition of a synthetic TLR4 agonist to further extend adjuvant performance.
T4Q VET (Pipeline Adjuvant)
T4Q VET is an emulsion-based adjuvant system combining INI-2002, a synthetic TLR4 agonist, with QSap™ VET, a veterinary-grade saponin. This formulation is designed to induce balanced Th1/Th2 immune responses by coupling innate immune activation with enhanced antigen presentation, supporting both humoral and cellular immunity. T4Q VET is intended to address the needs of challenging animal health vaccines, including those targeting complex pathogens, while maintaining the cost efficiency and scalability required for veterinary markets. Developed specifically for animal health applications, T4Q VET represents a next-generation adjuvant platform to support innovative and differentiated veterinary vaccine formulations.